Clinical Trial

Study of Healthy Aging and Physical Function With Elamipretide

Study acronym: SHAPE
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2025 (before its estimated March 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will utilize a daily dose of elamipetide for 4 weeks and will screen a sufficient number of subjects for 30 subjects to enroll in the study. The planned duration of the study includes baseline measurement, followed by 4 weeks intervention period, a midpoint (2week ±3days) check-in phone interview, and post intervention visits that mirror the baseline visits. After the last injection, subjects will enter the 2-week follow-up period, concluded by the end-of-study contact.
Trial Details
NCT Number NCT07275424
Lead Sponsor David Marcinek
Collaborators: Stealth BioTherapeutics Inc.
Conditions Aging, Healthy
Enrollment 30 participants
Start Date 2025-11-26
Primary Completion 2026-03-15 (estimated)
Study Completion 2026-04-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-10